Your browser doesn't support javascript.
Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial.
Lin, Dan-Yu; Baden, Lindsey R; El Sahly, Hana M; Essink, Brandon; Neuzil, Kathleen M; Corey, Lawrence; Miller, Jacqueline.
  • Lin DY; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill.
  • Baden LR; Brigham and Women's Hospital, Boston, Massachusetts.
  • El Sahly HM; Department of Medicine, Baylor College of Medicine, Houston, Texas.
  • Essink B; Meridian Clinical Research, Omaha, Nebraska.
  • Neuzil KM; Department of Medicine, University of Maryland, Baltimore.
  • Corey L; Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Miller J; Moderna, Cambridge, Massachusetts.
JAMA Netw Open ; 5(6): e2215984, 2022 06 01.
Article in English | MEDLINE | ID: covidwho-1888472
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / 2019-nCoV Vaccine mRNA-1273 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: JAMA Netw Open Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / 2019-nCoV Vaccine mRNA-1273 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: JAMA Netw Open Year: 2022 Document Type: Article